Pancreatic Cancer Drugs Global Market Report 2024
07 mars 2024 04h09 HE
|
Research and Markets
Dublin, March 07, 2024 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The pancreatic cancer drugs market size...
Lung Cancer Drugs Global Market Report 2024 - Regulatory Approvals and Increased Patient Awareness and Education Propel the Market
11 déc. 2023 11h58 HE
|
Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Lung Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The lung cancer drugs market size has grown...
Global Lung Cancer Drugs Market (2021 to 2030) - Featuring Bristol-Myers Squibb, Merck & Co and F. Hoffmann-La Roche Among Others
21 déc. 2021 04h33 HE
|
Research and Markets
Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Lung Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. This...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
14 oct. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
19 févr. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 19, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and...
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
16 déc. 2013 09h15 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage...
FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next
09 sept. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...
Stock Market Media Group Issues Nuvilex, Inc. Road to Phase III Clinical Trials Report
15 août 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 15, 2013) - Stock Market Media Group, a research and content development investor relations firm, issued its Third Quarter Update and the first installment of its...
Nuvilex, Inc. Acquisition Could Be Steal of the Century and Worth Billions
18 juil. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 18, 2013) - In a recently announced acquisition deal, Nuvilex, Inc. (OTCQB: NVLX), pulled off what can only be described as the steal of the century. The company...